A visionary in gastroenterology, Professor Thomas Borody is renowned for revolutionising the treatment of infectious and gut-related diseases. After completing his BSc(Med) and MB BS at UNSW in 1974, he gained expertise in parasitology and infectious diseases in the Solomon Islands before earning his MD at the Garvan Institute. His research journey took him to the Mayo Clinic in Minnesota, where he honed his skills in clinical research. He was awarded a PhD by the University of Newcastle and a DSc by UTS, Sydney. In 1984, Professor Borody founded the Centre for Digestive Diseases, a globally recognized institute pioneering therapies for gastrointestinal disorders. He is best known for developing the first triple therapy for Helicobacter pylori, a breakthrough that transformed peptic ulcer treatment. His Faecal Microbiota Transplantation (FMT) innovations have helped thousands with Clostridium difficile infections, colitis and autoimmune disorders. With over 300 publications and 160 patents registered in his distinguished career, he has advanced treatments for Crohn’s disease, ulcerative colitis, and resistant Helicobacter pylori infections. His groundbreaking research continues to shape the future of microbiome-based medicine, offering fresh hope to patients worldwide.